Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Silence Therapeutics plc
  6. Summary
    SLNCF   GB00B9GTXM62

SILENCE THERAPEUTICS PLC

(SLNCF)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
12/29/2021 01/04/2022 01/14/2022 01/18/2022 01/19/2022 Date
0(c) 6.75(c) 7.98(c) 6.71(c) 7.06 Last
34 200 117 100 600 Volume
-100.00% +18.22% -15.91% +5.22% Change
More quotes
Estimated financial data (e)
Sales 2021 13,5 M 18,4 M 18,4 M
Net income 2021 -42,8 M -58,3 M -58,3 M
Net cash position 2021 76,7 M 105 M 105 M
P/E ratio 2021 -
Yield 2021 -
Sales 2022 22,5 M 30,7 M 30,7 M
Net income 2022 -43,1 M -58,7 M -58,7 M
Net cash position 2022 73,4 M 100 M 100 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 443 M 602 M 604 M
EV / Sales 2021 27,1x
EV / Sales 2022 16,4x
Nbr of Employees 65
Free-Float -
More Financials
Company
Silence Therapeutics plc is a biotechnology company. The Company is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger... 
More about the company
Ratings of Silence Therapeutics plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SILENCE THERAPEUTICS PLC
10:00aSilence Therapeutics - Head of Molecular Design Dr. Marie Wikstrom Lindholm Appointed t..
AQ
01/18Silence Therapeutics' Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to..
BU
01/05Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virt..
AQ
2021European ADRs Move Higher in Thursday Trading
MT
2021SILENCE THERAPEUTICS : Data presented at 2021 ASH annual meeting showed durable reductions..
PU
2021SILENCE THERAPEUTICS : SLN124 a GalNAc Conjugated 19-mer Double-Stranded siRNA Reduces Iro..
PU
2021New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in H..
AQ
2021Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volu..
CI
More news
News in other languages on SILENCE THERAPEUTICS PLC
2021Les ADR européens sont en hausse jeudi
More news
Chart SILENCE THERAPEUTICS PLC
Duration : Period :
Silence Therapeutics plc Technical Analysis Chart | SLNCF | GB00B9GTXM62 | MarketScreener
Income Statement Evolution
Managers and Directors
Mark A. Rothera President, CEO & Executive Director
Craig A. Tooman Chief Financial Officer
Iain Gladstone Ross Non-Executive Chairman
Giles Campion Executive Director & Chief Medical Officer
Alistair William Gray Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SILENCE THERAPEUTICS PLC0.00%602
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707